Reduction in abdominal symptoms (CFAbd-Score), faecal M2-pyruvate-kinase and Calprotectin over one year of treatment with Elexacaftor-Tezacaftor-Ivacaftor in people with CF aged ≥12 years – The RECOVER study

Already at birth, most infants with cystic fibrosis (CF) have exocrine pancreatic insufficiency (PI). Malabsorption, malnutrition and growth failure follow PI, particularly with advancing age and evolving CF lung disease. Intestinal epithelial dysfunction, particularly in the setting of PI, can be associated with inflammation, dysbiosis and dysmotility, partial or complete bowel obstruction either in infancy with meconium ileus (MI) or later in life with constipation or distal intestinal obstruction syndrome (DIOS) [1].

Source: Journal of Cystic Fibrosis - October 7, 2023 Category: Respiratory Medicine Authors: Jochen G. Mainz, Karen Lester, Basil Elnazir, Michael Williamson, Ed McKone, Des Cox, Barry Linnane, Carlos Zagoya, Franziska Duckstein, Anton Barucha, Jane C. Davies, Paul McNally, RECOVER Study Group Tags: Original Article Source Type: research